Financing ·
Marpai, Inc. entered into securities purchase agreements with accredited investors to sell 12,100 shares of newly…
MRAIMarpai, Inc.
Marpai, Inc. entered into securities purchase agreements with accredited investors to sell 12,100 shares of newly designated Series A Preferred Stock at $1,000 per share, generating approximately $12,100,000 in gross proceeds. The initial closing is expected on July 31, 2026. Each preferred share converts into common stock at a price of $1.00 and carries an 8% dividend payable in common stock upon liquidity events or conversion. Mitchell Companies led the investment, with Steve Mitchell appointed as a board observer for two years under a separate agreement. The company agreed to file a registration statement within 60 days of closing. Marpai operates in the healthcare technology industry, providing Third-Party Administration and Pharmacy Benefit Management services.